Zobrazeno 1 - 10 of 20 pro vyhledávání: '"van Steeg TJ"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration.
Autor: Berkhout J; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, The Netherlands., Fairman D; Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, Hertfordshire, UK., van Noort M; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, The Netherlands., van Steeg TJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, The Netherlands.
Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Sep 11. Date of Electronic Publication: 2024 Sep 11.
Zobrazit plný text záznamu
5
Akademický článek
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Autor: Berends SE; Hospital Pharmacy, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands. s.e.berends@amc.uva.nl.; Gastroenterology & Hepatology Department, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands. s.e.berends@amc.uva.nl., van Steeg TJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., Ahsman MJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., Singh S; Progenity, San Diego, CA, USA., Brandse JF; Gastroenterology & Hepatology Department, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands., D'Haens GRAM; Gastroenterology & Hepatology Department, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands., Mathôt RAA; Hospital Pharmacy, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.
Publikováno v: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2019 Dec; Vol. 46 (6), pp. 543-551. Date of Electronic Publication: 2019 Sep 05.
Zobrazit plný text záznamu
6
Akademický článek
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Autor: Betts A; a Department of Biomedicine Design , Pfizer Inc. , Cambridge , MA , USA., Keunecke A; b LAP&P , The Netherlands., van Steeg TJ; b LAP&P , The Netherlands., van der Graaf PH; c Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research , RA Leiden , The Netherlands., Avery LB; d Department of Biomedicine Design , Pfizer Inc. , Andover , MA , USA., Jones H; a Department of Biomedicine Design , Pfizer Inc. , Cambridge , MA , USA., Berkhout J; b LAP&P , The Netherlands.
Publikováno v: MAbs [MAbs] 2018 Jul; Vol. 10 (5), pp. 751-764. Date of Electronic Publication: 2018 May 14.
Zobrazit plný text záznamu
7
Akademický článek
Extending a Systems Model of the APP Pathway: Separation of β - and γ -Secretase Sequential Cleavage Steps of APP.
Autor: van Maanen EMT; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., van Steeg TJ; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Ahsman MJ; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Michener MS; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Savage MJ; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Kennedy ME; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Kleijn HJ; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Stone J; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.)., Danhof M; Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S., M.J.A.); and Merck & Company, Inc., Kenilworth, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.S.) m.danhof@lacdr.leidenuniv.nl.
Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 Jun; Vol. 365 (3), pp. 507-518. Date of Electronic Publication: 2018 Mar 21.
Zobrazit plný text záznamu
8
Akademický článek
Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation.
Autor: Goto A; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Tagawa Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Moriya Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Sato S; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Yamamoto M; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Wakabayashi T; Central Nervous System Drug Discovery Unit, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Tsukamoto T; Inflammation Drug Discovery Unit Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., DeJongh J; Leiden Advanced Pharmacokinetics & Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., van Steeg TJ; Leiden Advanced Pharmacokinetics & Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., Moriwaki T; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan., Asahi S; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Co. Ltd, Kanagawa, Japan.
Publikováno v: Biopharmaceutics & drug disposition [Biopharm Drug Dispos] 2017 Dec; Vol. 38 (9), pp. 543-552. Date of Electronic Publication: 2017 Nov 09.
Zobrazit plný text záznamu
9
Akademický článek
Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation.
Autor: Goto A; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Tagawa Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Moriya Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Sato S; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Furukawa Y; Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Wakabayashi T; Central Nervous System Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Tsukamoto T; Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., DeJongh J; Leiden Advanced Pharmacokinetics & Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., van Steeg TJ; Leiden Advanced Pharmacokinetics & Pharmacodynamics (LAP&P) Consultants, Leiden, The Netherlands., Moriwaki T; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Asahi S; Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
Publikováno v: Biopharmaceutics & drug disposition [Biopharm Drug Dispos] 2017 Sep; Vol. 38 (6), pp. 373-380. Date of Electronic Publication: 2017 May 23.
Zobrazit plný text záznamu
10
Akademický článek
Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.
Autor: van Maanen EM; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., van Steeg TJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Michener MS; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Savage MJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Kennedy ME; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Kleijn HJ; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Stone JA; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.)., Danhof M; Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands (E.M.T.v.M., T.J.v.S.); Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands (E.M.T.v.M., M.D.); and Merck Research Laboratories, Whitehouse Station, New Jersey (M.S.M., M.J.S., M.E.K., H.J.K., J.A.S.) m.danhof@lacdr.leidenuniv.nl.
Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Apr; Vol. 357 (1), pp. 205-16. Date of Electronic Publication: 2016 Jan 29.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje